Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs

Fineline Cube Sep 13, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined...

Company Deals

Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies

Fineline Cube Sep 13, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Deals

Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations

Fineline Cube Sep 13, 2024

MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round,...

General/Other

Leadership Shuffle at China’s National Health Commission: Liu Jinfeng Steps in as Deputy Director

Fineline Cube Sep 13, 2024

The Ministry of Human Resources and Social Security has announced key leadership changes within the...

Company Deals

Autobio Diagnostics Partners with MBL to Advance Microbial Mass Spectrometry Technology

Fineline Cube Sep 13, 2024

Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market,...

Company Medical Device

Yestar Healthcare’s 2024 Interim Report Reflects Impact of Volume-Based Procurement on Revenue

Fineline Cube Sep 13, 2024

Yestar Healthcare Holdings Co., Ltd., a leading distributor and service provider for in vitro diagnostic...

Company Drug

Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives

Fineline Cube Sep 12, 2024

Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...

Company Policy / Regulatory

FDA Uncovers Data Management Failures in Medical Device Labs, Assessing Regulatory Impact

Fineline Cube Sep 12, 2024

Medical device manufacturers relying on laboratory services for testing and validation data have come under...

Company Legal / IP R&D

Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology

Fineline Cube Sep 12, 2024

Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization

Fineline Cube Sep 12, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Deals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Fineline Cube Sep 12, 2024

Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...

Policy / Regulatory

China Aims to Fortify Insurance Industry by 2035 with New State Council Directives

Fineline Cube Sep 12, 2024

The State Council has issued the “Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting...

Company Drug

Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy

Fineline Cube Sep 12, 2024

Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval

Fineline Cube Sep 12, 2024

Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting

Fineline Cube Sep 12, 2024

Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...

Company Deals

CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment

Fineline Cube Sep 11, 2024

CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing...

Company

Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape

Fineline Cube Sep 11, 2024

South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...

Company Deals

Gilead Sciences Partners with AI Firm Genesis Therapeutics to Develop Novel Small-Molecule Therapies

Fineline Cube Sep 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into...

Company Deals

Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies

Fineline Cube Sep 11, 2024

Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...

Company Deals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

Fineline Cube Sep 11, 2024

Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...

Posts pagination

1 … 350 351 352 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.